Diabetes drug canagliflozin slows advanced kidney disease
Article written by Bruce Sylvester The diabetes drug canagliflozin, which has already shown efficacy in slowing kidney disease, is also effective among patients with advanced kidney disease.
Article written by Bruce Sylvester The diabetes drug canagliflozin, which has already shown efficacy in slowing kidney disease, is also effective among patients with advanced kidney disease.
Article written by Bruce Sylvester Hydroxychloroquine treatment for lupus has no significant impact on heart rhythm, researchers reported on Nov 2, 2020 at the American College of Rheumatology/ACR… read more.
Article written by Bruce Sylvester Patients with chronic kidney disease have achieved improved outcomes with dapagliflozin treatment, researchers reported on October 8, 2020 in the NEJM/New England Journal… read more.
Article written by Bruce Sylvester Researchers from a large European study, which included the UK, report that while patients are often able to reduce risks of cardiovascular events… read more.
AstraZeneca announced high-level results from Farxiga’s (dapagliflozin) Phase III DAPA-CKD trial showed a statistically significant and clinically meaningful effect on its primary endpoint of a composite of worsening… read more.
Aurinia Pharmaceuticals Inc., a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, announced that the FDA has accepted the filing of its New Drug Application… read more.
Shield Therapeutics plc a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru/Accrufer (ferric maltol), notes the recent publication in Nephrology… read more.
Mallinckrodt Plc announced that the Cardiovascular And Renal Drugs Advisory Committee of the U.S. FDA voted to recommend approval for its investigational agent terlipressin to treat adults with… read more.
The European Medicines Agency’s (EMA) human medicines committee (CHMP) has recommended eight medicines for approval at its June 2020 meeting.
The Phase III study FIDELIO-DKD evaluating the efficacy and safety of BAY 94 8862 (finerenone), from Bayer, versus placebo when added to standard of care for chronic kidney… read more.
ChemoCentryx, Inc. confirmed that the Company has submitted a New Drug Application (NDA) to the FDA for avacopan for the treatment of patients with ANCA-associated vasculitis. The Company’s… read more.
Mallinckrodt Plc ,announced that the Cardiovascular And Renal Drugs Advisory Committee of the FDA will, as expected, hold a virtual meeting to review data on terlipressin, an investigational… read more.